Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Septerna, Inc. ( (SEPN) ) just unveiled an announcement.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal ...

Novo Nordisk A/S scrapped a partnership with Hims & Hers Health Inc. after less than two months, saying the U.S. company is using 'deceptive marketing' to sell copycat versions of its obesity ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ending of its deal with Hims & Hers jeopardizes the healthcare platform's ...

Hims & Hers stock fell 35% after Novo Nordisk ended their partnership on Monday. Novo Nordisk stopped the deal because Hims sold a cheaper version of Wegovy.

Septerna (NASDAQ:SEPN – Get Free Report) is projected to announce its Q1 2025 earnings results on Thursday, June 26th. Analysts expect the company to announce earnings of ($0.38) per share for ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.